IL1B and systemic-onset juvenile idiopathic arthritis: Finally, chronic lung disease in the setting of SJIA and MAS has been increasingly recognized in the past decade, in parallel with widespread use of anti-cytokine (IL-1 and IL-6) biologics [12–14].